A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.

ABSTRACT:

Background

The clinical benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) is controversial. This study aimed to explore novel gene signature to predict outcome benefit of postoperative 5-Fu-based therapy in stage II CRC.

Methods

Gene-expression profiles of stage II CRCs from two datasets with 5-Fu-based adjuvant chemotherapy (training dataset, n = 212; validation dataset, n = 85) were analyzed to identify the indicator. A systemic approach by integrating gene-expression and protein-protein interaction (PPI) network was implemented to develop the predictive signature. Kaplan-Meier curves and Cox proportional hazards model were used to determine the survival benefit of adjuvant chemotherapy. Experiments with shRNA knock-down were carried out to confirm the

SUBMITTER: Cao B 

PROVIDER: S-EPMC5729289 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature